CD8A and neoplasm: Another recent phase I/Ib study tested the efficacy of a personalized neoantigen vaccine in newly diagnosed GBM patients and found the vaccination promoted neoantigen-specific CD4+ and CD8+ T cell responses and additionally increased the number of tumor-infiltrating T cells [57].